Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
PHILADELPHIA, Oct. 30, 2017 /CNW/ -- Hemispherx Biopharmara, Inc. (NYSE American: HEB), based in Philadelphia, focused on pharmaceuticals, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer, will present live at VirtualInvestorConferences.com on November 2.
DATE: Thursday, November 2, 2017
TIME: 10:45 AM ET
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register and run the online system check to save time and receive event updates.
Learn more about the event at www.VirtualInvestorConferences.com.
Recent Company Highlights
- August 2017: Hemispherx Human Safety Study Of Intranasal Ampligen® With Influenza Vaccine Shows Ampligen Was Generally Well-Tolerated
- August 2017: Hemispherx Biopharma Announces Collaboration With Millions Missing Canada To Bring Medication To Canadians For Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- August 2017: Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended June 30, 2017
About Hemispherx Biopharma, Inc.
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.
Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen®. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because Ampligen® is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials.
The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company's Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name "Naturaferon") for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection.
The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE Hemispherx Biopharma, Inc.
For further information: VirtualInvestorConferences.com: John Viglotti, VP, Investor Relations Products and Services, Phone 201 360 6767, Mobile 212 729 8350, [email protected]